ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Therapeutic effect of Fuzheng Yixin decoction on cardiac insufficiencythe soluble guanylyl cyclase-cyclic guanosine monophosphate-protein kinase G pathway in a doxorubicin-induced dilated cardiomyopathy rat model.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the effect of Fuzheng Yixin decoction (, FZYX) and explore its underlying mechanisms in doxorubicin-induced dilated cardiomyopathy (DCM) rat model.
methodsSprague-Dawley rats were intraperitoneally injected with doxorubicin for 6 consecutive weeks. Ultra-high-perform ance liquid chromatography Q-exactive mass spectrometry was utilized to obtain mass spectrum data for FZYX. The rats were then intragastrically injected with low-dose FZYX, high-dose FZYX, or captopril for 4 weeks. Serum N-terminal pro-brain natriuretic peptide, transthoracic echocardiography, haematoxylin and eosin and Masson staining, electron microscopy, and immunohistochemistry were used to evaluate the efficacy of FZYX. Differentially expressed genes and metabolites in the myocardial tissue of DCM rats following FZYX intervention were subsequently identified through transcriptomics and non-targeted metabolomics. Finally, the influence of FZYX on the expression of natriuretic peptide precursor A (Nppa), natriuretic peptide precursor B (Nppb), soluble guanylyl cyclase (sGC), protein kinase G (PKG), and PKG-1α in DCM rats was verified through quantitative polymerase chain reaction (qPCR), Western blotting (WB) based on the results of transcriptomics and non-targeted metabolomics analyses.
resultsFZYX alleviated body weight loss; inhibited ventricular dilatation; restored impaired heart function, ruptured sarcomeres and mitochondrial damage, and pathological changes; and reduced collagen deposition. Transcriptomic and non-targeted metabolomic results revealed that FZYX regulated the expression of sGC-cyclic guanosine monophosphate (cGMP)-PKG pathway-related genes (Nppa, Nppb) and metabolites such as cGMP, 5'-guanylic acid, adenosine. qPCR and WB demonstrated that FZYX suppressed the expression of Nppa and Nppb and increased the expression of sGC, which led to a further increase in the level of PKG and PKG-1α.
conclusionThese findings suggest that the cardioprotective effect of FZYX may be mediated through the restoration of the sGC-cGMP-PKG signaling pathway. FZYX may provide a new strategy for clinical application against DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.